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In vitro studies have revealed that human immunodeficiency virus-1 (HIV-1) Nef functionally interacts with amino acid
residues in the cytoplasmic tail of major histocompatibility complex class I (MHC-I) molecules, reducing their expression on
the cell surface and protecting them from cytotoxic T lymphocyte (CTL) lysis. To obtain a better understanding of Nef’s effects
in vivo, it would be helpful to have a mouse model system. However, it is not known whether Nef will affect murine MHC-I
proteins. We find that Nef downmodulates human MHC-I HLA-A2 more efficiently than murine MHC-I molecules in HeLa cells
and that Nef does not function efficiently in murine endothelial cells. Studies with chimeric molecules indicate that the MHC-I
cytoplasmic tail is primarily responsible for species-specific differences. However, there are also effects attributable to the
extracellular domain. © 2002 Elsevier Science (USA)INTRODUCTION
HIV-1Nef is a 27-kDa myristoylated protein that has
multiple activities defined in vitro. These include the
following: alterations in signaling with disruption of pro-
apoptotic pathways (Wolf et al., 2001; Geleziunas et al.,
2001; Mahlknecht et al., 2000; Yoon et al., 2001; Ro-
bichaud and Poulin, 2000); increased viral infectivity; T
cell activation; and CD28, CD4, and MHC-I downmodu-
lation (for review, see Saksela, 1997). Based on in vivo
studies, it is known that an intact nef gene is necessary
for the timely development of AIDS in most humans and
monkeys (Deacon et al., 1995; Kestler et al., 1991; Kirchoff
et al., 1995). In addition, the ability of Nef to downmodu-
late MHC-I has been shown to be important in vivo
(Munch et al., 2001).
Downmodulation of cell-surface molecules by Nef re-
quires sequences within their respective cytoplasmic
tails. Nef has been shown to directly bind the cytoplas-
mic tail of CD4 and is thought to physically link CD4 to
the endocytosis apparatus (for review, see Doms and
Trono, 2000). Nef’s effects on MHC-I seem to be different
in that the dileucine motif necessary for Nef to promote
accelerated endocytosis is not needed for MHC-I down-
modulation (Mangasarian et al., 1999). In addition, MHC-I
downmodulation in HeLa cells is not blocked by a dom-
inant negative dynamin molecule that inhibits endocyto-
sis (Swann et al., 2001; Le Gall et al., 2000). Nef has not
yet been demonstrated to bind the cytoplasmic tail of
MHC-I; however, there is evidence that two cellular fac-
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120tors able to bind Nef are necessary for efficient MHC-I
downmodulation, PI 3-kinase and PACS-1 (Piguet et al.,
2000; Swann et al., 2001; Kim et al., 1999). PI-3 kinase
regulates trafficking from the trans-Golgi network (TGN)
to other intracellular organelles such as lysosomes and
endosomes (Stack and Emr, 1994; Brown et al., 1995;
Burd and Emr, 1998; Gaffet et al., 1997; Gary et al., 1998).
PACS-1 promotes TGN localization by interacting with
specific cytoplasmic tail sequences and causing Golgi-
budded vesicles to be recycled (Wan et al., 1998). Thus,
one possible model is that Nef binds to the cytoplasmic
tail of MHC-I protein and facilitates a sequential interac-
tion with PI 3-kinase and PACS-1 that leads to intracel-
lular localization.
An analysis of Nef’s in vivo role would be facilitated if
a small animal model for HIV disease was available, but
attempts at studying HIV disease in mice have been
thwarted by multiple blocks to viral transmission and HIV
gene expression (Hart et al., 1989; Alkhatib et al., 1996a;
Winslow and Trono, 1993; Newstein et al., 1990; Alonso
et al., 1992) (although recent studies indicate that the rat
may be a more promising model system (Keppler et al.,
2002)). In the process of understanding blocks to HIV
infection in murine cells, a great deal has been learned
about which cellular molecules are necessary for virus
production (Garber et al., 1998; Dragic et al., 1996;
Alkhatib et al., 1996b). Thus, species-specific differences
might similarly allow us to better understand which cel-
lular partners are necessary for Nef’s activity. Expression
of HIV-1 Nef in mice and in a variety of murine cell lines
leads to downmodulation of CD4 (Rhee and Marsh, 1994;
Brady et al., 1993; Anderson et al., 1993); however, it is
not known whether murine cells support Nef-mediatedKey Words: HIV; Nef; MHC class I; murine.
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© 2002 Elsevier Science (USA)MHC-1 protein downmodulation. We show here that ex-
pression of Nef in human HeLa cells leads to the pref-
erential downmodulation of HLA-A2 compared with mu-
rine MHC-I allotypes. We have also found that murine
endothelial cells (and other murine lines) are relatively
defective at MHC-I downmodulation over a tenfold range
of Nef protein levels. These data suggest that there are
species-specific requirements for downmodulation
MHC-I that must be overcome before a mouse model for
HIV disease can be realized.
RESULTS
The study of HIV disease pathogenesis would be fa-
cilitated by a small animal model. As a result, much effort
has been spent developing a system in which HIV can
replicate in murine cells. In this context, it is important to
determine whether Nef, a protein critical for normal HIV
disease pathogenesis, functions in murine cells. A mu-
rine cellular environment can support Nef-mediated
CD4-downmodulation (Rhee and Marsh, 1994; Brady et
al., 1993; Anderson et al., 1993); however, it is not known
whether Nef downmodulates MHC-I in murine cells.
To test this, we utilized a system in which Nef was
expressed in a replication-defective adenoviral vector
(adeno-Nef). This system allows efficient Nef expression
even in cells that are difficult to transfect. Moreover,
because of its high titer, we are able to titrate the amount
of Nef added over a broad range of Nef levels. We have
previously shown that when Nef is introduced into hu-
man cell lines using adenovirus, it efficiently downmodu-
lated only wild-type MHC-I molecules containing the
required cytoplasmic tyrosine residue. Furthermore, a
mutant version of adeno-Nef that lacks the required
SH3-binding domain is appropriately defective (Swann et
al., 2001). Thus, adeno-Nef downmodulates MHC-1 anti-
gens in a manner consistent with that which has been
reported for other expression systems.
Thus far, three amino acid residues in the cytoplasmic
tail have been demonstrated to be important for Nef-
mediated MHC-1 protein downmodulation (Fig. 1A). A
sequence comparison between human and mouse MHC
class I allotypes indicated that although the required
tyrosine residue at position 320 is present in murine
allotypes, the others are not (Fig. 1A). Therefore, it was
not surprising to observe that at a relatively low m.o.i.
(200:1), adeno-Nef was able to downmodulate HLA-A2,
but not H2-Kd or H2-Dd in HeLa cells (Fig. 2). To deter-
mine whether this resulted from sequence differences in
the cytoplasmic tail, a chimeric molecule composed of
the H2-Kd extracellular domain and the HLA-A2 trans-
membrane and cytoplasmic domain was constructed
(Fig. 1B). As expected, it was efficiently downmodulated
by Nef (Fig. 2).
At a higher m.o.i. (400:1) of adeno-Nef, we observed
significant downmodulation of H2-Kd, but not H2-Dd (Fig.
3). Specific downmodulation of H2Kd at multiple higher
m.o.i.s (and Nef levels) was consistently observed (Fig.
4), and similar results were obtained when these HeLa
cells were transduced with a VSV-G-pseudotyped PLAP
indicator HIV strain (data not shown; Collins and Balti-
more, 1999). To determine whether the difference in sen-
sitivity to Nef of H2-Kd versus H2-Dd was due to se-
quence differences in the cytoplasmic tail, chimeric mol-
ecules were constructed (Figs. 1C and 1D). These were
made such that a small portion of the extracellular do-
main plus the transmembrane domain and the cytoplas-
mic tail came from one allotype, and the remainder of the
extracellular domain came from the other. When cells
expressing these allotypes were treated with adeno-Nef,
we found that there were effects of both halves of these
molecules, and that neither chimera (Kd/Dd or Dd/Kd)
downmodulated as efficiently as the wild-type H2-Kd mol-
ecule (Fig. 3). These data suggest that the extracellular
domain can influence Nef-mediated MHC-I downmodu-
lation.
Additional evidence that the extracellular domain af-
fected Nef-mediated MHC-I downmodulation is shown in
Fig. 5 for a higher m.o.i. (750:1). The H2-Kd cytoplasmic
tail attached to the HLA-A2 extracellular domain did not
respond to Nef as well as the unmodified H2-Kd molecule
(Fig. 5).
Multiple studies using immunoblot analysis to deter-
mine relative Nef levels indicated that all of the HeLa cell
lines tested were similarly infectable and expressed sim-
ilar amounts of Nef protein (data not shown).
Because of the differences between the murine and
human MHC-I proteins, a murine system responsive to
Nef might require the expression of HLA-A2 in the
mouse. However, it is not known whether Nef will down-
modulate MHC-I in a murine cellular background. Nef is
known to downmodulate MHC-I in a host of human cell
types (T cell, B cell, HeLa, astrocyte, fibroblast, and
melanoma lines) (Greenberg et al., 1998; Swann et al.,
2001; Schwartz et al., 1996; Piguet et al., 2000; Wang et
al., 1998; Mangasarian et al., 1999). Therefore, we ex-
pressed human HLA-A2 heavy chain and a compatible
light chain (2-microglobulin, see Materials and Meth-
ods) in a murine Balb/C endothelial cell line that was
known to be infectable by adenovirus. Coexpression of
both chains was necessary because human heavy
chains do not interact very well with murine light chains.
(By contrast, murine heavy chains associate readily with
human light chains (Perarnau et al., 1988; Pedersen et al.,
1995.) Based on immunoprecipitation and surface stain-
ing with the conformationally sensitive monoclonal anti-
body W6/32 (Parham et al., 1979), these cells expressed
properly folded HLA-A2 protein (Figs. 6A and 6B). For
unclear reasons, murine cells expressing HLA-A2 were
more resistant to adenovirus infection than the parent
cell line. However, using the replication-deficient adeno-
viral system, we were able to compensate for this by
adjusting the m.o.i. (Fig. 6D). Over a tenfold range of
m.o.i.s (from 400:1 to 4000:1), there was only a small
amount of downmodulation of HLA-A2 in murine cells
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(Figs. 6B, 6C, and 6D show data for an m.o.i. of 2000:1).
For reference, immunoblot analysis indicated that
Balb-A2 cells transduced at an m.o.i. of 2000:1 achieved
Nef levels similar to that of HeLa cells transduced at an
m.o.i. of 500:1 m.o.i. (data not shown). Thus, these data
suggest that a species-specific process (such as a pro-
tein–protein interaction or posttranslational modifica-
tion), is important for optimal Nef-mediated MHC-I down-
modulation.
Similarly, Balb/C endothelial cells transfected to ex-
press H2-Kd or H2-Dd did not downmodulate well over a
similar range of m.o.i.s. (Balb/C lines were transfected
because the parental cell line did not express detectable
MHC-I unless induced with interferon-.) We also tested
murine 3T3 cells and mastocytoma cells (data not
shown) with similar results.
To determine whether the cytoplasmic tail affected
susceptibility to Nef in this cellular background, a chi-
FIG. 1. (A) Amino acid sequence alignment of a selection of human and murine cytoplasmic tails. Amino acid sequences previously demonstrated
to be important for Nef’s effects are highlighted (Cohen et al., 1999; Le Gall et al., 1998; Lalanne et al., 1983; Margulies et al., 1983; Joly and Oldstone,
1991). (B) Schematic diagram of HLA-A2/H2-Kd chimeric constructs. Shaded boxes represent H2-Kd sequence. TM, transmembrane; Cyto, cytoplasmic
tail. (C) Schematic diagram of H2-Dd/H2-Kd chimeric constructs. Hatched boxes represent H2-Dd sequence. (D) Sequence comparison between H2-Kd
and H2-Dd. The dark, thin line indicates the region that was swapped to make the Kd/Dd and Dd/Kd chimera. The dashed line indicates the probable
location of the transmembrane domain, and the gray line indicates the position of the cytoplasmic tail.
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meric molecule composed of the H2-Kd cytoplasmic tail
and the HLA-A2 extracellular domain was tested. As
shown in Fig. 6, the A2/Kd chimera was downmodulated
less efficiently than either H2-Kd or HLA-A2. Thus, there
is an effect of the extracellular domain on Nef’s ability to
downmodulate this MHC-I protein.
DISCUSSION
We have found that there are species-specific differ-
ences that will make it difficult to construct a mouse
model of HIV disease. In human cells, Nef preferentially
downmodulated HLA-A2 as compared to H2-Kd and
downmodulated H2-Kd somewhat more efficiently than
H2-Dd. In murine endothelial cells, equivalent amounts of
Nef protein did not achieve as much downmodulation as
was observed in human HeLa cells. More experiments
will be needed to understand these differences. How-
ever, one possibility is that HLA-A2 fails to interact with
murine proteins that affect its processing or transport in
a way that is important for Nef-mediated MHC-I down-
modulation.
Previous studies have shown that Nef efficiently down-
modulates CD4 in a murine cellular background (Brady
et al., 1993; Anderson et al., 1993). However there are
multiple studies indicating mechanistic differences be-
tween Nef-mediated MHC-I and CD4 downmodulation,
and therefore, this result is not too surprising. The dif-
ferences we have found in Nef’s ability to downmodulate
HLA-A2 in murine versus human cells suggest that an
effective mouse model will require additional human
factors. Future experiments will involve transfecting mu-
rine cell lines with human PI 3-kinase and PACS-1 to
determine whether these proteins can rescue Nef’s ac-
tivity.
We have also noted a reproducible effect of the extra-
cellular domain of MHC-I on Nef-mediated MHC-I down-
modulation. These data suggest that there may be some
FIG. 2. Nef preferentially downmodulates human MHC-I allotypes. HeLa cells expressing the indicated MHC-I molecule were transduced with
adeno-Nef or adenovector at a 200:1 m.o.i. and were harvested the next day for flow cytometric analysis. (A) Flow cytometric analysis of MHC-I
expression. Cells were stained using an antibody specific to the indicated allotype. The filled curve represents the level of MHC-I present on cells
treated with the control virus, and the gray line represents the result of Nef expression. (B) Quantitation of the flow cytometric plots. Fold
downmodulation was determined for each sample by dividing the mean fluorescence intensity of MHC-I for the control sample by that of the Nef
sample. The mean fold downmodulation for at least three experiments  SEM is shown.
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communication between the extracellular domain and
the cytoplasmic tail that can influence Nef’s effects. More
studies are needed to determine the precise mechanism
for this result. However, these data give some impetus to
exploring whether different human HLA-A and HLA-B
allotypes respond differently to Nef. If so, the role of Nef
could potentially help explain why an individual’s MHC-I
genotype is important for HIV disease prognosis (Car-
rington et al., 1999; Gao et al., 2001).
MATERIALS AND METHODS
Antibodies
Antibodies for flow cytometry were obtained from the
following sources: anti-H-2Kd/H-2Dd (Accurate Scientific);
anti-H-2Dd (Serotec); biotin-conjugated anti-H-2Kd and
anti-H-2Kb (PharMingen); anti-HLA-A2 (One Lambda);
anti-HLA-A,B,C clone W6/32 (Accurate Scientific); phyco-
erythrin (PE)-conjugated anti-human CD4 (Caltag). The
following secondary antibodies were used in this study:
UltraAvidin-R-PE (Leinco Technologies); goat F(AB)2
anti-mouse IgM R-PE (BioSource); and goat anti-mouse
IgG-R-PE (Caltag). HIV-1 Nef antiserum for Western blot-
ting was obtained from Dr. Ronald Swanstrom, the NIH
AIDS Research and Reference Reagent Repository, Divi-
sion of AIDS, NIAID, NIH (Shugars et al., 1993).
DNA constructs
The cDNAs for H2-Kd, and H2-Dd in the mammalian
expression vector pRSVneo, were provided by Dr. Han-
sen (Washington University School of Medicine). An
HLA-A2 cDNA in the mammalian expression vector
pCDNA (K/A2 pCDNA) was provided by Hidde Ploegh’s
laboratory (Harvard Medical School). A cDNA encoding
2-microglobulin was provided by Malini Raghavan (Uni-
versity of Michigan). MSCV IRES GFP was provided by
Luke Van Parijs (California Institute of Technology). A
plasmid expressing HLA-A2 and 2-microglobulin sepa-
FIG. 3. Nef can downmodulate certain murine allotypes at higher protein levels. HeLa cells expressing the indicated MHC-I molecule were
transduced with adeno-Nef or adenovector at a 500:1 m.o.i. and were harvested the next day for flow cytometric analysis. (A) Flow cytometric analysis
of MHC-I expression. Cells were stained using an antibody specific to the indicated allotype. The filled curve represents the level of MHC-I present
on cells treated with the control virus, and the gray line represents the result of Nef expression. (B) Quantitation of the flow cytometric plots. Fold
downmodulation was determined for each sample by dividing the mean fluorescence intensity of MHC-I for the control sample by that of the Nef
sample. The mean fold downmodulation for at least three experiments  SEM is shown.
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rated by an internal ribosome entry site (IRES) was con-
structed from MSCV IRES GFP as follows: chimp 2-
microglobulin cDNA (encodes a protein with the same
amino acid sequence as human 2-microglobulin) was
amplified using PCR cloned into the SalI/NcoI sites of
MSCV IRES GFP, replacing GFP. The BamHI to XhoI
fragment of K/A2 pCDNA was then cloned into the BglII
and XhoI sites of MSCV to create A2 IRES 2. This
construct was used for ecotropic retrovirus production
(Pear et al., 1993) and used to transduce Balb/C cells.
To make A2 with the Kd tail (A2/Kd), silent sequence
changes were introduced to create an AgeI site near the
cytoplasmic tail. This was accomplished using PCR mu-
tagenesis. The oligonucleotides used to make the 5
fragment were as follows: 5-GGGAATTCATGGTACCGT-
GCACGCTGCTC-3 and 5-CACAGCAGCGACCACAG-
CACCGGTGATCACAGCTCCAAA-3. The oligonucleo-
tides used to make the 3 fragment in the HLA-A2 cDNA
were as follows: 5-CACAGCAGCGACCACAGCACCGGT-
GATCACAGCTCCAAA-3 and 5-GCGATATCCATGTGT-
TCCATTTATTTTGT-3. The oligonucleotides used to
make the 5 fragment in the Kd cDNA were as follows:
5-GTCGACTCTAGATGGCACCCTGC-3 and 5-GGAGCT-
GCAATAGTCACCGGTGCTGTGGTGGCTTTTGTG-3. The
oligonucleotides used to make the 3 fragment in the Kd
cDNA were as follows: 5-CACAAAAGCCACCACAG-
CACCGGTGACTATTGCAGCTCC-3 and 5-TCATGTCTG-
GATCCCCCGAGTTGG-3. The PCR products were di-
gested with XbaI and BamHI and cloned back into their
respective original expression plasmids. The HLA-A2
and H2-Kd constructs were then digested with AgeI and
BglII or BamHI, respectively. The 5 A2 fragment, still in
the pCDNA vector, was then ligated with 3Kd fragment
(pCDNA A2/Kd) and the 5Kd fragment, still in the pRSV
vector, was ligated with the 3A2 fragment (pRSV Kd/A2).
The BamHI and XhoI fragment of pCDNA A2/Kd was then
ligated into the MSCV IRES 2 digested with XhoI and
BglII to create A2/Kd IRES 2.
A mutant version of the H2-Kd cDNA was constructed
in which the tyrosine residue in the cytoplasmic tail was
changed to an alanine. This was accomplished using a
PCR-based strategy described previously (Higuchi,
1990). The oligonucleotides used to make the 5 frag-
ment were as follows: 5-GTCGACTCTAGATGGCAC-
CCTGC-3 and 5-GGTGGAAAAGGAGTGAACGCTGCTC-
TGGCTCCAGGCTCC. The oligonucleotides used to
make the 3 fragment were as follows: 5-GGAGCC-
TGGAGCCAGAGCAGCGTTCACTCCTTTTCCACC-3 and
5-TCATGTCTGGATCCCCCGAGTTGG-3. The resulting
mutated fragment was digested with XbaI and BamHI
and cloned back into the original expression plasmid.
The construct was sequenced to ensure that only the
intended alterations had been made.
To make the Kd/Dd and Dd/Kd chimeric constructs, the
BamHI fragment (Dd) and the XbaI to BamHI fragment
(Kd) were isolated and digested with NspI. This enzyme
cut Kd at nucleotide position 839 and Dd at nucleotide
position 848, which are at an overlapping region in the
protein sequence just 5 to the transmembrane region
(see Figs. 1C and 1D). The 5 fragment of Kd was ligated
to the 3 fragment of Dd (Kd/Dd) and vice versa (Dd/Kd).
These chimeras were cloned into pRSV and sequenced
to assure that only the intended changes were made.
FIG. 4. Differential downmodulation of HLA-A2 versus H2Kd can be overcome at high Nef levels. HeLa cells expressing the indicated MHC-I
molecule were transduced with adeno-Nef or adenovector at a 200:1 or 750:1 m.o.i. and were harvested the next day for flow cytometric analysis.
(A) Flow cytometric analysis of MHC-I expression. Cells were stained using an antibody specific to the indicated allotype. The filled curve represents
the level of MHC-I present on cells treated with the control virus, and the gray line represents the result of Nef expression. (B) Western blot analysis
demonstrating that Nef levels are roughly proportional to m.o.i.
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Cell lines and culture conditions
Balb/C murine aortic endothelial cell line was ob-
tained from Dr. Robert Auerbach at the University of
Wisconsin. HeLa and Balb/C cell lines were main-
tained in DMEM supplemented with 2 mM glutamine,
10% FCS, penicillin, and streptomycin. To create stable
cell lines expressing the indicated MHC-I constructs,
HeLa cells or Balb/C endothelial cells were trans-
fected using calcium phosphate and were selected in
puromycin for HLA-A2 pCDNA constructs or Geneticin
(Life Technologies) for H2-Kd/H2-Dd pRSV constructs.
A Balb/C line expressing HLA-A2 or HLA-A2 with an
H2Kd tail were created using an MSCV retroviral con-
struct that expressed both the heavy chain and the
2-microglobulin (see above and Pear et al., 1993). All
cell lines were sorted by fluorescence-activated cell
sorting (FACS) to obtain cells expressing high
amounts of the MHC-I construct.
FIG. 5. Downmodulation of human and murine allotypes at high Nef levels specifically requires specific sequences in the HLA-A2 cytoplasmic tail.
HeLa cells expressing the indicated MHC-I molecule were transduced with adeno-Nef or adenovector at a 750:1 m.o.i. and were harvested the next
day for flow cytometric analysis. (A) Flow cytometric analysis of MHC-I expression. Cells were stained using an antibody specific to the indicated
allotype. The filled curve represents the level of MHC-I present on cells treated with the control virus, and the gray line represents the result of Nef
expression. (B) Quantitation of the flow cytometric plots. Fold downmodulation was determined for each sample by dividing the mean fluorescence
intensity of MHC-I for the control sample by that of the Nef sample. The mean fold downmodulation for at least three experiments  SEM is shown.
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Adenovirus transduction
A replication-defective adenoviral vector expressing
HIV-1 Nef was constructed as described previously
(Swann et al., 2001). The control virus (adenovector) is
identical to adeno-Nef except that it lacks the Nef open
reading frame. Adenovirus transductions were per-
formed as follows: HeLa or Balb/C cells were incubated
with adenovirus (estimated m.o.i. 200:1–4000:1 depend-
ing on the cell line) in DMEM supplemented with 2%
FCS. After 2 h, an equal volume of fresh DMEM plus 10%
FCS was added. Cells were then incubated for 20–24 h
prior to harvest.
Analysis by fluorescence-activated cell sorting (FACS)
To assess the levels of cell-surface class I molecules,
cells were incubated with primary antibody for 20 min at
4°C in FACS buffer (PBS, 2% FCS, 1% HEPES, 1% sodium
azide), washed, incubated with the appropriate second-
ary antibody (see above), washed again, and analyzed
on a Becton–Dickinson FACScan using CELLQuest soft-
ware.
Metabolic labeling and immunoprecipitation
Balb/C cell lines expressing HLA-A2 and 2-micro-
globulin were pulse labeled for 15 min with 200 Ci/ml
Pro-mix (Amersham). Lysates were precleared overnight
with control antibody and protein A plus protein G aga-
rose (Oncogene). The next day, samples were immuno-
precipitated with monoclonal antibody W6/32 and
washed in RIPA buffer (TBS 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS). Samples were separated by
10% SDS–PAGE. The gel was treated with Enhance
(NEN) according to the manufacturer’s protocol, dried,
and exposed to Kodak Biomax MS film.
Western blot analysis of Nef expression levels
Cells were lysed in NP-40 lysis buffer (0.5% NP-40, 50
mM Tris, pH 7.3, 5 mM MgCl2, 1 mM PMSF), and equal
FIG. 6. Nef does not efficiently downmodulate MHC-I murine endothelial cells. (A) Immunoprecipitation of properly folded HLA-A2 from murine cells.
Balb/C cells expressing HLA-A2 were metabolically labeled, lysed, and immunoprecipitated with the conformationally sensitive monoclonal antibody
W6/32 or control ascites (see Materials and Methods for more details). (B) Flow cytometric analysis of MHC-I expression. Balb/C cells transfected
with the indicated MHC-I molecule were transduced with adeno-Nef or adenovector and harvested the next day for flow cytometric analysis. Results
shown are for a 400:1 m.o.i. (Kd and Dd) and 2000:1 (A2 and A2/Kd). There was no difference in the amount of downmodulation achieved in these cell
lines over a range of m.o.i.s from 400:1 to 4000:1. In Balb/C A2 cells, an m.o.i. of 2000:1 yielded Nef levels similar to an m.o.i. of 500:1 in HeLa cells
(data not shown). Cells were stained using an antibody specific to the indicated allotype-specific antibody. The filled curve represents the level of
MHC-I present on cells treated with the control virus, and the gray line represents the result of Nef expression. (C) Quantitation of the flow cytometric
plots. Fold downmodulation was determined for each sample by dividing the mean fluorescence intensity of MHC-I for the control sample by that of
the Nef sample. The mean fold downmodulation for at least three experiments  SEM is shown. (D) Western blot analysis demonstrating similar Nef
levels in the transduced cell lines at the m.o.i.s used for these experiments.
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amounts of protein were loaded onto a 15% SDS–poly-
acrylamide gel. Equal protein loading was confirmed by
staining the polyacrylamide gel with Coomasie brilliant
blue after transfer. Samples were electroblotted onto
Immobilon, blocked in 5% milk in TBS (10 mM Tris, pH
8.0, 140 mM NaCl), and probed with HIV-1 Nef antiserum
(see above). Blots were developed using Supersignal
(Pierce) according to the manufacturer’s instructions.
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